Lung Cancer | Specialty

Dr. Patel on the FDA Approval of Durvalumab in NSCLC

February 17th 2018

Jyoti D. Patel, MD, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discusses the FDA approval of durvalumab (Imfinzi) in patients with non

FDA Approves Durvalumab for Locally Advanced NSCLC

February 17th 2018

The FDA has approved durvalumab for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following chemoradiotherapy.

Dr. Stinchcombe on the KEYNOTE-189 Trial in Lung Cancer

February 17th 2018

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the KEYNOTE-189 trial in patients with lung cancer.

Immunotherapy Poised to Move Forward Into Stage III NSCLC

February 16th 2018

A panel of several of the world’s foremost experts on immunotherapy in lung cancer discuss durvalumab and other emerging approaches for stage III NSCLC.

Avelumab Falls Short in Phase III NSCLC Trial

February 16th 2018

Avelumab (Bavencio) missed the primary endpoint of improving overall survival in pretreated patients with non–small cell lung cancer, according to findings from the phase III JAVELIN Lung 200 Trial.

Dr. Sampath on Safety of Immunotherapy Plus Radiation in Lung Cancer

February 15th 2018

Sagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses the safety profile of immunotherapy in combination with radiation in the treatment of patients with lung cancer.

Dr. Sequist Discusses Combination Regimens in EGFR+ NSCLC

February 14th 2018

Lecia V. Sequist, MD, associate professor of medicine, Harvard Medical School, Mary B. Saltonstall Chair, Oncology, Massachusetts General Hospital Center, discusses combination regimens for patients with EGFR-positive non-small cell lung cancer (NCSLC).

Bounty of Novel Drugs Ushers In New Era for ALK-Positive NSCLC

February 13th 2018

ALK inhibitors have followed a rapid trajectory from bench to bedside, taking over from chemotherapy as standard frontline treatment for patients with advanced non– small-cell lung cancer with ALK gene rearrangements.

Better Utilization of Broad Panel NGS Possible in 2018

February 13th 2018

A recent study of oncologists’ use of next-generation sequencing to test for actionable genetic mutations reveals a stark gap between the appropriateness and the actual utilization of these tests.

FDA Grants Priority Review to Lorlatinib for ALK+ NSCLC

February 13th 2018

The FDA has granted a priority review to a new drug application for lorlatinib for use in patients with ALK-positive metastatic non–small cell lung cancer who have progressed on 1 or more ALK TKIs.

Dr. Levy Discusses Pembrolizumab in NSCLC

February 13th 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses pembrolizumab (Keytruda) in non-small cell lung cancer.

Expert Recaps Immunotherapy Milestones in NSCLC

February 12th 2018

Thomas Eldridge Stinchcombe, MD, recaps recent data with immunotherapy as a single agent and in combination in NSCLC and what challenges the field is facing in 2018.

Dr. Stinchcombe Discusses the PACIFIC Trial for NSCLC

February 7th 2018

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the PACIFIC trial for patients with non–small cell lung cancer (NSCLC).

Dr. Erhunmwunsee on Factors of Disparity in Lung Cancer Treatment

February 6th 2018

Loretta Erhunmwunsee, MD, thoracic surgeon, assistant professor of surgery, City of Hope, discusses the factors that contribute to disparities in the treatment of patients with lung cancer.

Frontline Nivolumab/Ipilimumab Improves PFS in High TMB NSCLC

February 5th 2018

The combination of nivolumab and ipilimumab improved progression-free survival compared with chemotherapy in treatment-naïve patients with high tumor mutation burden non–small cell lung cancer.

Dr. Salgia on Importance of Molecular Markers in Lung Cancer

February 1st 2018

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of molecular markers in lung cancer.

Dr. Sequist Distinguishes Osimertinib From Earlier NSCLC TKIs

February 1st 2018

Lecia V. Sequist, MD, associate professor of medicine, Harvard Medical School, Mary B. Saltonstall Chair, Oncology, Massachusetts General Hospital Center, discusses the tolerability of a new third-generation T790-specific inhibitor, osimertinib (Tagrisso).

Dr. Massarelli on First-Line ALK+ NSCLC Treatment

January 30th 2018

Erminia Massarelli, MD, PhD, MS, associate clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the adoption of alectinib (Alecensa) as the first-line therapy in the treatment of patients with ALK-positive non–small cell lung cancer (NSCLC).

Emerging Immunotherapy Options for Metastatic NSCLC

January 30th 2018

Immunotherapy with Antiangiogenics in NSCLC

January 30th 2018